Catatonia as a risk factor for the development of neuroleptic malignant syndrome: Report of a case following treatment with clozapine

World Journal of Biological Psychiatry

Volumn 10, Issue 1, 2009, Pages 70-73

  Paparrigopoulos, Thomas ^a   Tzavellas, Elias ^a   Ferentinos, Panagiotis ^a   Mourikis, Iraklis ^a   Liappas, John ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Catatonia; Clozapine; Neuroleptic malignant syndrome; Risk factor

Indexed keywords

CLOZAPINE; CREATINE KINASE; DIAZEPAM; FRUCTOSE BISPHOSPHATE ALDOLASE; LORAZEPAM;

ADULT; ANAMNESIS; ARTICLE; BIPOLAR DISORDER; CASE REPORT; CATALEPSY; CATATONIA; CLINICAL FEATURE; CREATINE KINASE BLOOD LEVEL; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIFFERENTIAL DIAGNOSIS; DISEASE EXACERBATION; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; LABORATORY TEST; LEUKOCYTOSIS; LIFE EVENT; MUSCLE HYPERTONIA; NEUROLEPTIC MALIGNANT SYNDROME; PSYCHOMOTOR DISORDER; PSYCHOSIS; RIGIDITY; SCHIZOPHRENIA; TREATMENT DURATION; TREMOR;

ANTIPSYCHOTIC AGENTS; CATATONIA; CLOZAPINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MIDDLE AGED; NEUROLEPTIC MALIGNANT SYNDROME; PSYCHOTIC DISORDERS; RISK FACTORS; SCHIZOPHRENIA, CATATONIC;

EID: 61649084954     PISSN: 15622975     EISSN: 18141412     Source Type: Journal    
DOI: 10.1080/15622970701287369     Document Type: Article

References (49)

1. American Psychiatric Association (2000)American Psychiatric Association, Washington, DC
2. Ananth, J., Parameswaran, S. and Gunatilake, S. (2004) Side effects of atypical antipsychotic drugs. Curr Pharm Des, 10, pp. 2219-2229.
3. Caroff, SN, Mann, SC, Lazarus, A., Sullivan, K. and MacFadden, W. (1991) Neuroleptic malignant syndrome: Diagnostic issues. Psychiatr Ann, 21, pp. 130-147.
4. Caroff, SN, Mann, SC, Keck Jr, PE and Francis, A. (2000) Residual catatonic state following neuroleptic malignant syndrome. J Clin Psychopharmacol, 20, pp. 257-259.
5. (2004) Catatonia: From psychopathology to neurobiology, American Psychiatric Press, Washington, DC
6. Caroll, BT and Boutros, NN (1995) Clinical electroencephalograms in patients with catatonic disorders. Clin Electroencephalogr, 26, pp. 60-64.
7. Caroll, BT and Goforth, HW (1995) Serum iron in catatonia. Biol Psychiatry, 38, pp. 776-777.
8. Carroll, BT and Lee, JW (2004) Catatonia is a risk factor for neuroleptic malignant syndrome. J Clin Psychiatry, 65, pp. 1722-1723.
9. Caroll, BT and Taylor, RE (1997) The non dichotomy between lethal catatonia and neuroleptic malignant syndrome. J Clin Psychopharmacol, 17, pp. 235-238.
10. Chakraborty, N. and Johnston, T. (2004) Aripiprazole and neuroleptic malignant syndrome. Int Clin Psychopharmacol, 19, pp. 351-353.
11. Dent, J. (1995) Catatonic syndrome following recovery from neuroleptic malignant syndrome. J Intellect Disabil Res, 39, pp. 457-459.
12. Dew, RE, Rosenquist, PB and McCall, WV (2005) Aripiprazole for agitation in a 13-year-old girl with neuroleptic malignant syndrome. Int J Adolesc Med Health, 17, pp. 187-188.
13. Fink, M. (1996) Neuroleptic malignant syndrome and catatonia. One entity or two?. Biol Psychiatry, 39, pp. 1-4.
14. Fink, M. and Taylor, MA (2001) The many varieties of catatonia. Eur Arch Psychiatry Clin Neurosci, 251, p. I8.
15. Fink, M. and Taylor, MA (2003) Catatonia: A clinician's guide to diagnosis and treatment, Cambridge University Press, Cambridge
16. Francis, A., Divadeenam, K. and Petrides, G. (1997) Advances in the diagnosis and treatment of catatonia. Convuls Ther, 12, pp. 259-261.
17. Franzen, D., Burkhard, J., Corti, N., Schupbach, D., Fontanel, D. and Staubli, M. (2006) Neuroleptic malignant syndrome after 30 years treatment with clozapine: A rarely seen differential diagnosis on intensive care units. Anasthesiol Intensivmed Nottfallmed Schmertzher, 41, pp. 125-127.
18. Fricchione, G. (1989) Catatonia: A new indication for benzodiazepines?. Biol Psychiatry, 26, pp. 761-765.
19. Hasan, S. and Buckley, P. (1998) Novel antipsychotics and the neuroleptic malignant syndrome: A review and critique. Am J Psychiatry, 155, pp. 1113-1116.
20. Jahanshahi, M., Jenkins, H., Brown, RG and Marsden, CD (1995) Self-initiated versus externally triggered movements. Brain, 118, pp. 913-933.
21. Kahlbaum, KL Die Katatonie oder das Spannungsirresein, Verlag August Hirshwald, Berlin
22. Kleist, K. (1943) Die Katatonie. Nervenarzt, 16, pp. 1-10.
23. Kobayashi, A., Kawanishi, C. Matsumura, T. et al. (2006) Quetiapine-induced neuroleptic malignant syndrome in dementia with Lewy bodies: A case report. Prog Neuropsychopharmacol Biol Psychiatry, 30, pp. 1170-1172.
24. Koch, M., Chandragiri, S., Rizvi, S., Petrides, G. and Francis, A. (2000) Catatonic signs in neuroleptic malignant syndrome. Compr Psychiat, 41, pp. 73-75.
25. Kontaxakis, VP, Vaidakis, NM, Christodoulou, GN and Valergaki, HC (1990) Neuroleptic-induced catatonia or a mild form of neuroleptic malignant syndrome?. Neuropsychobiology, 23, pp. 38-40.
26. Kontaxakis, VP, Christodoulou, GN, Markidis, MP and Havaki-Kontaxaki, BJ (1988) Treatment of a mild form of neuroleptic malignant syndrome with oral diazepam. Acta Psychiatr Scand, 78, pp. 396-398.
27. (1989) The Neuroleptic malignant syndrome and related conditions, American Psychiatric Press, Washington, DC
28. Leibold, J., Patel, V. and Hasan, RA (2004) Neuroleptic malignant syndrome associated with ziprasidone in an adolescent. Clin Ther, 26, pp. 1105-1108.
29. Lew, TY and Tollefson, G. (1983) Chloropromazine-induced neuroleptic syndrome and its response to lorazepam. Biol Psychiatry, 18, pp. 1441-1446.
30. Mann, SC, Caroff, SN, Bleier, JR, Welz, WKR, Kling, MA and Hayashida, M. (1986) Lethal catatonia. Am J Psychiatry, 143, pp. 1374-1381.
31. Mann, SC, Caroff, SN, Fricchione, G. and Campbell, C. (2000) Central dopamine hypoactivity and the pathogenesis of neuroleptic malignant syndrome. Psychiatr Ann, 30, pp. 363-374.
32. Meltzer, HY (2000) Massive serum creatine kinase increases with atypical antipsychotic drugs: What is the mechanism and the message?. Psychopharmacology (Berl), 150, pp. 349-350.
33. Miyaoka, H., Shishkura, K., Otsubo, T., Moramatsu, D. and Kamijima, K. (1997) Diazepam-responsive neuroleptic malignant syndrome: A diagnostic subtype?. Am J Psychiatry, 153, p. 882.
34. Nisijima, K. and Ishiguro, T. (1995) Cerebrospinal fluid levels of monoamine metabolites and gamma-aminobutyric acid in neuroleptic malignant syndrome. J Psychiatr Res, 29, pp. 233-244.
35. Norgard, NB and Stark, JE (2006) Olanzapine-associated neuroleptic malignant syndrome. Pharmacotherapy, 26:8, pp. 1180-1182.
36. Northoff, G., Wenke, J. and Pflug, B. (1996) Increase of serum creatinine phosphokinase in catatonia: An investigation in 32 acute catatonic patients. Psychol Med, 26, pp. 547-553.
37. Northoff, G., Pfennig, A., Krug, M., Leschinger, A. and Borgets, B. (2000) Delayed onset of late movement-related cortical potentials and abnormal response to lorazepam in catatonia. Schizophr Res, 44, pp. 193-211.
38. Philbrick, KL and Rummans, TA (1994) Malignant catatonia. J Neuropsychiatry Clin Neurosci, 6, pp. 1-13.
39. Raja, M., Altavista, MC, Cavallari, S. and Lubich, L. (1994) Neuroleptic malignant syndrome and catatonia. A report of three cases. Eur Arch Psychiatry Clin Neurosci, 243, pp. 299-303.
40. Rosebush, P. and Stewart, T. (1989) A prospective analysis of 24 episodes of neuroleptic malignant syndrome. Am J Psychiatry, 146, pp. 717-725.
41. Sachdev, P., Kruk, J., Kneebone, M. and Kissane, D. (1995) Clozapine-induced neuroleptic malignant syndrome: Review and report of new cases. J Clin Psychopharmacol, 15, pp. 365-371.
42. Taylor, MA (1990) Catatonia. A review of the behavioural neurologic syndrome. Neuropsychiatr Neuropsychol Behav Neurol, 3, pp. 48-72.
43. Tsai, JH, Yang, P., Yen, JY, Chen, CC and Yang, MJ (2005) Zotepine-induced catatonia as a precursor in the progression to neuroleptic malignant syndrome. Pharmacotherapy, 25, pp. 1156-1159.
44. Wang, HC and Hsieh, Y. (2001) Treatment of neuroleptic malignant syndrome with subcutaneous apomorphine monotherapy. Mov Disord, 16, pp. 765-767.
45. Wetzel, H., Heuser, I. and Benkert, O. (1987) Stupor and affective state: Alleviation of the psychomotor disturbances by lorazepam and recurrence of symptoms after Ro 15-1788. J Nerv Ment Dis, 175, pp. 240-242.
46. White, DAC (1992) Catatonia and the neuroleptic malignant syndrome-a single entity?. Br J Psychiatry, 161, pp. 558-560.
47. White, DAC and Robins, AH (1991) Catatonia: Harbinger of the neuroleptic malignant syndrome. Br J Psychiatry, 158, pp. 419-421.
48. Woodbury, MM and Woodbury, MA (1992) Neuroleptic-induced catatonia as a stage in the progression toward neuroleptic malignant syndrome. J Am Acad Child Adolesc Psychiatry, 31, pp. 1161-1164.
49. Zalsman, G., Lewis, R., Konas, S., Loebstein, O., Goldberg, P. Burguillo, F. et al. (2004) Atypical neuroleptic malignant syndrome associated with risperidone treatment in two adolescents. Int J Adolesc Med Health, 16, pp. 179-182.